UPDATE 2-Alnylam’s gene-silencing efforts get $2 bln Blackstone backing
Blackstone Group Inc said on
Monday it would invest $2 billion in Alnylam Pharmaceuticals Inc
through an equity-and-debt deal, giving the drugmaker a
financial boost without tapping into currently volatile stock
markets for funds.
Monday it would invest $2 billion in Alnylam Pharmaceuticals Inc
through an equity-and-debt deal, giving the drugmaker a
financial boost without tapping into currently volatile stock
markets for funds.
Posted by Reuters
